BioSpace News Archive

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, presented the development details of its novel off-the-shelf (OTS) personalized immunotherapy, Bria-OTS™, summarized in a poster session held at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Scilex Holding Company, a nearly 100% majority-owned subsidiary of Sorrento Therapeutics, Inc. announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors.

MediciNova, Inc. announced that the Phase 2 clinical trial of MN-166 in hospitalized COVID-19 patients at risk for developing acute respiratory distress syndrome has completed enrollment.

Trishula Therapeutics, Inc., today announced preliminary results from an ongoing Phase 1 trial evaluating TTX-030 in combination with budigalimab (investigational anti-PD-1) and FOLFOX for the first-line treatment of patients with locally advanced/metastatic HER2 negative gastric or gastroesophageal junction cancer.

Surf Bio, Inc., a biopharmaceutical company commercializing a novel drug stabilization platform, announced a $16 million Series Seed round of funding.

CytoRecovery, Inc., a leader in the marker free enrichment, sorting, and recovery of live cells, presented recent study results at the American Association for Cancer Research (AACR) Annual Meeting 2022 currently being held in New Orleans.

Growing applications of nanorobotics in tissue engineering, dental surgery, cellular assistance in inflammatory responses, and other areas of healthcare are some major factors driving market revenue growth.

Lysogene (FR0013233475 – LYS) (Paris:LYS), announced today that it has exercised its option to enter into an exclusive worldwide license agreement with Yeda Research and Development Co Ltd, the commercial arm of the Weizmann Institute of Science, for the development and commercialization of a gene therapy candidate for the treatment of neuronopathic Gaucher disease and Parkinson disease (PD) with GBA1 mutations.

Gain Therapeutics, Inc., a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary computational discovery platform, presented new pre-clinical data from its Parkinson’s Disease program.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented three preclinical poster presentations and one preclinical oral presentation at the 2022 American Cancer Research Association (AACR) Annual Meeting.